Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Active, not recruiting · NCT02962063 · Registry updated 2026-09-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-09 | NCT02962063 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Memorial Sloan Kettering Cancer Center | 753 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | United States | 189 |
| Memorial Sloan Kettering Bergen | Montvale | United States | 193 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Memorial Sloan Kettering Commack | Commack | United States | 189 |
| Memorial Sloan Kettering Nassau | Uniondale | United States | 193 |
| Memorial Sloan Kettering Rockville Centre | Rockville Centre | United States | 11 |
| Memorial Sloan Kettering Westchester | Harrison | United States | 204 |